PROM1 and hepatocellular carcinoma: Clinically, RALYL expression is correlated with poor prognosis (P = 0.036), poor differentiation (P = 0.044), metastasis (P = 0.032), CD133 expression (P = 0.003), and TGF-β2 expression (P = 0.029) in HCC patients.